Akorn-Strides, LLC Announces Tenth ANDA Submission
25 8월 2006 - 9:34PM
Business Wire
Akorn-Strides, LLC, a joint venture company formed between Akorn,
Inc. (AMEX:AKN) and Strides Arcolab Limited (NSE:STAR)(BSE:532531),
today announced that it has submitted its tenth Abbreviated New
Drug Application (ANDA) with the Office of Generic Drugs. The
Akorn-Strides joint venture was formed in September 2004 as the
result of a development, manufacturing, and marketing partnership
between Akorn and Strides. Since that time, Strides has been
developing the ANDA products and Akorn has been filing the
regulatory submissions on behalf of the joint venture. The first
ANDA submission for the Akorn-Strides joint venture was filed in
April 2006. Arthur S. Przybyl, Akorn's President and Chief
Executive Officer stated, "Since the formation of the joint
venture, the submission of the tenth ANDA filing represents a
significant milestone. Strides is performing its responsibilities
to the joint venture ahead of schedule." Arun Kumar, Executive Vice
Chairman and Managing Director of Strides stated, "We are delighted
with the pace of filings through the joint venture with Akorn. We
are confident of playing a significant role providing a strong
pipeline and supplies to convert Akorn-Strides into a significant
hospital player in the US. About Akorn, Inc. Akorn, Inc.
manufactures and markets sterile specialty pharmaceuticals. Akorn
has manufacturing facilities located in Decatur, Illinois and
Somerset, New Jersey and markets and distributes an extensive line
of hospital and ophthalmic pharmaceuticals. Additional information
is available at the Company's website at www.akorn.com. About
Strides Arcolab Limited Strides, listed on the Bombay Stock
Exchange Limited (532531) and National Stock Exchange of India
Limited (STAR), is one of India's largest exporters of branded
generic pharmaceutical products. Strides manufactures
pharmaceuticals formulations in various dosage forms, including
capsules, tablets, liquid injectables and is one of the world's top
five manufacturers of softgel capsules. Strides also has the only
globally dedicated softgel facility for hormones. In addition,
Strides undertakes contract research and the manufacturing of
specialty chemicals for various multinational companies. Strides
has a major presence in various developing countries such as
Africa, Latin America and Asia as well as in developed markets such
as the U.S., Canada and part of Europe. Strides is one of the
largest Indian supplier of institutionally funded aid projects and
is an approved supplier to the Global Drug Facility, UNICEF, and
MSF amongst others. Strides has 13 manufacturing plants spread
across the U.S., Brazil, Mexico, Italy, Poland and India. This
broad manufacturing network facilitates partnering with global
organizations ranging from UNICEF and WHO-Global Drug Facility to
European and American pharmaceutical multinationals, private
labelers and distribution chains. Strides has product registrations
in over 37 countries around the world and has earned ISO 9001, ISO
14001 and GMP accreditations including USFDA. Strides employs
approximately 1,700 people across the globe. Strides also has a
marketing presence in over 50 countries. Materials in this press
release may contain information that includes or is based upon
forward-looking statements within the meaning of the Securities
Litigation Reform Act of 1995. Forward-looking statements give our
expectations or forecasts of future events. You can identify these
statements by the fact that they do not relate strictly to
historical or current facts. They use words such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe," and
other words and terms of similar meaning in connection with a
discussion of future operating or financial performance. In
particular, these include statements relating to future steps we
may take, prospective products, future performance or results of
current and anticipated products, sales efforts, expenses, the
outcome of contingencies such as legal proceedings, and financial
results. Any or all of our forward-looking statements here or in
other publications may turn out to be wrong. They can be affected
by inaccurate assumptions or by known or unknown risks and
uncertainties. Many such factors will be important in determining
our actual future results. Consequently, no forward-looking
statement can be guaranteed. Our actual results may vary
materially, and there are not guarantees about the performance of
our stock. Any forward-looking statements represent our
expectations or forecasts only as of the date they were made and
should not be relied upon as representing our expectations or
forecasts as of any subsequent date. We undertake no obligation to
correct or update any forward-looking statements, whether as a
result of new information, future events or otherwise, even if our
expectations or forecasts change. You are advised, however, to
consult any further disclosures we make on related subjects in our
reports filed with the SEC. In particular, you should read the
discussion in the section entitled "Cautionary Statement Regarding
Forward-Looking Statements" in our most recent Annual Report on
Form 10-K, as it may be updated in subsequent reports filed with
the SEC. That discussion covers certain risks, uncertainties and
possibly inaccurate assumptions that could cause our actual results
to differ materially from expected and historical results. Other
factors besides those listed there could also adversely affect our
results.
Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024